EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
December 9, 2024
EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and